NCT01017536已完成2 期
Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of AERAS-402 in HIV-infected, BCG-vaccinated Adults With CD4+ Lymphocyte Counts Greater Than 350 Cells/mm3
Aeras1 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2009年12月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- CD4+ Lymphocyte Count
研究概览
简要总结
This was a Phase II, randomized, double-blind, placebo-controlled trial conducted at 1 site in South Africa. A total of 26 subjects were randomized 1:1 to receive 2 doses of either AERAS-402 at 3 x 10^10 vp (N=13) or placebo (N=13) on Study Days 0 and 28. Dose-escalation to a second group of 40 subjects was planned, but although no safety concerns were identified, the sponsor decided not to continue the study.
详细描述
Further study details as provided by Aeras.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 21 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 21 years through 45 years (i.e., subject had not yet reached his/her 46th birthday at day of randomization).
- •Had completed the written informed consent process prior to undergoing any screening evaluations.
- •Had BCG vaccination at least 5 years previously, documented by medical history or presence of scar.
- •Females: Ability to avoid pregnancy for at least 6 months after receiving the last study vaccination: Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) must have avoided pregnancy from 28 days prior to administration of the study vaccine and must have agreed to avoid pregnancy through at least 6 months after receiving the last study vaccination. Acceptable methods of avoiding pregnancy included a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), or use of a combination of at least two forms of acceptable contraception: hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), and the use of a condom or a diaphragm; or the use of a condom or a diaphragm combined with spermicide.
- •Was able to carry out activities of daily living independently.
- •Had Body Mass Index (BMI) of at least 19 (wt./ht.2) by nomogram.
- •Had ability to complete follow-up period as required by the protocol.
- •Was able and willing to commit to avoiding elective surgery for at least 6 months after receiving the last study vaccination.
- •Was able and willing to stay in contact with the study site for the duration of the study.
- •Had committed to simultaneous enrollment in Aeras Vaccine Development Registry Protocol.
- •Had laboratory evidence of human immunodeficiency virus (HIV) infection, defined as a positive HIV-1 ELISA test plus a positive confirmatory test (e.g., a second HIV-1 ELISA, PCR, or rapid ELISA).
- •Had four (4) (for Group 1) or three (3) (for Group 2)* CD4+ lymphocyte count tests, each performed at least four days apart within the 42-day screening period, with at least three (for Group 1) or two (for Group 2) CD4+ lymphocyte count results greater than 350 cells / mm
- •Not currently receiving antiretroviral drugs.
- •Committed to not participate in any other clinical trials during the first 12 months of participation in this study.
排除标准
- •Acute illness.
- •Fever ≥37.5°C.
- •Significant symptomatic infection.
- •Used immunosuppressive medication within 42 days prior to randomization (inhaled and topical corticosteroids were permitted).
- •Received immunoglobulin or blood products within 42 days prior to randomization.
- •Received any investigational drug therapy or vaccine within 182 days prior to randomization.
- •History of having received any adenovirus-vector-based vaccine.
- •Medical history that may have compromised the evaluation of safety of the subject in the study (e.g., diabetes, seizure disorder, sickle cell disease).
- •Pregnant or breastfeeding female, or intention to become pregnant during the study within 6 months after receiving the last study vaccination.
- •Liver function tests >Grade 2 per the toxicity table.
- •Currently receiving treatment for TB, or evidence of active TB disease based on history, physical examination, chest X-ray, or laboratory evaluation (INH prophylaxis was permitted).
研究组 & 干预措施
Placebo
Placebo Comparator
Thirteen subjects received placebo vaccine that did not contain any AERAS-402.
干预措施: Placebo (Biological)
Investigational Vaccine
Experimental
Thirteen subjects received active vaccine 3 x 10^10 vp AERAS-402.
干预措施: AERAS-402 (Biological)
结局指标
主要结局
CD4+ Lymphocyte Count
时间窗: CD4+ counts from samples collected on Study days 0 and 182.
Assess the effect of AERAS-402 on the CD4+ lymphocyte count after 6 months in HIV-infected, BCG-vaccinated adult subjects with no evidence of active tuberculosis (TB disease) Change in cells/mm\^3 pre-vaccination to Study Day 182
次要结局
- Mtb-specific T Cell Response in HIV-infected BCG-vaccinated Adult Subjects With no Evidence of TB Disease(Study days 28 and 56)
- Change in HIV Viral Load in HIV-infected, BCG-vaccinated Adult Subjects Before and After Administration of AERAS-402 (From Day 1 to Day 182)(6 months (day 182) post Study Day 0 vaccination.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of AS012 in Subjects With Non-segmental VitiligoNon-segmental VitiligoNCT04487860Ache Laboratorios Farmaceuticos S.A.327
已完成
2 期
Trial of Pimasertib With SAR245409 or Placebo in Ovarian CancerOvarian CancerNCT01936363EMD Serono65
已完成
2 期
Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative ColitisUlcerative ColitisNCT01336465Genentech, Inc.124
已完成
2 期
A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe PsoriasisPsoriasisNCT05096364Akeso251
已完成
2 期
A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy AdultsInfluenza ANCT02623322Genentech, Inc.124